SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 [language] = "en-us"

Di |2021-10-21T23:00:00+02:00Ottobre 21st, 2021|Categorie: Coronavirus NEJM|

To the Editor: We conducted a global, randomized, placebo-controlled, phase 1–2–3 pivotal trial in which two 30-μg doses of BNT162b2 (Pfizer–BioNTech) were administered 21 days apart (ClinicalTrials.gov number, NCT04368728). These doses of vaccine had ...

Continua a leggere
 0